Luca Arecco: Crucial evidences from the world BRCA BCY study
Luca Arecco, Research Fellow at the Jules Bordet Institute and a Medical Oncology Resident at Ospedale Policlinic San Martino, shared on X:
“Other crucial evidences from the world BRCA BCY study
Presented at SABCS24 by Matteo Lambertini the role of RRM and RRSO in young pts w previous diagnosis of BC:
RRM: High OS, DFS and BCFI
RRSO: High OS, DFS and BCFI
Congrats.”
Luca Arecco is a Research Fellow at the Jules Bordet Institute and a Medical Oncology Resident at Ospedale Policlinic San Martino. His work centeres on breast cancer research, with a particular emphasis on treating young women with the disease.
Matteo Lambertini is an adjunct professor and consultant in medical oncology at the IRCCS Policlinico San Martino Hospital and the University of Genova in Italy. He specializes in managing breast cancer in young women, particularly addressing fertility and pregnancy-related issues post-diagnosis.
Lambertini’s notable research includes using GnRH agonists during chemotherapy to preserve ovarian function and studying the safety of pregnancy after breast cancer. He also serves on the scientific boards of ESMO, ESHRE, and AIOM for fertility preservation in cancer patients.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023